Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetanus toxoid
- Development stage
- Approved
- Lead developer
- Parent
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Subcutaneous
01
Overview
**Tetanus toxoid** is a detoxified, nonpathogenic form of tetanospasmin, the neurotoxin produced by *Clostridium tetani*. It is used as an active-immunization antigen to induce toxin-neutralizing antibodies and immunologic memory that prevent tetanus; vaccine products containing tetanus toxoid are commonly adsorbed to aluminum salts and are often supplied in combination with diphtheria and/or pertussis antigens. In the United States, routine tetanus protection is generally delivered through DTaP, Tdap, or Td combination vaccines rather than monovalent tetanus-toxoid products. ([cdc.gov](https://www.cdc.gov/tetanus/vaccines/index.html))
- Brand names
- TDVAXTenivac
- Other names
- TTtetanus toxoid vaccine
Beyond the preview
Go deeper on tetanus toxoid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetanus toxoid.